This year NICE has been updating the clinical guideline on the management of type 2 diabetes. Boehringer Ingelheim has welcomed and contributed to NICE’s extensive consultations on the draft guideline and acknowledges that NICE has now addressed many of the issues seen in the initial draft. The current updated guideline published this month[i] now reflects a much more pragmatic approach to patient centred care and is representative of current glucose lowering therapies. I am pleased that the new clinical guideline will help to improve the care of patients living with type 2 diabetes.
Since 1996, the number of people living with diabetes in England has more than doubled to 3.2 million. [ii] It is estimated that 2.7 million people are currently diagnosed with diabetes and a further 500,000 people have the disease but do not know it.ii If trends continue, this number will rise to 4 million people by 2025.ii Poorly managed diabetes is the cause of 20,000 early deaths per year[iii] and diabetes accounts for around 10 percent of the annual NHS budget, or about £10 billion a year.ii
As documented in our health policy briefing which I helped to launch in Parliament earlier this year,[iv] Boehringer Ingelheim has been calling for all relevant diabetes guidelines to adopt an individualised approach to patient care that enables patient-centred prescribing in line with the principles of medicine optimisation. Previous draft guidelines have appeared to be heavily focussed on short-term cost efficiencies and failed to acknowledge the importance to patients of hypoglycaemic episodes and weight gain associated with type 2 diabetes.
I am pleased to see that the new NICE guideline does favour a more individualised approach to patient care. This will help to ensure that medicines are tailored to the individuals’ needs and circumstances, and that patients are offered the effective treatments they deserve.
What do you think about the new guideline on the management of type 2 diabetes? Please leave a comment here and tell me what you think.
Professor Klaus Dugi, Managing Director / Medical Director Boehringer Ingelheim UK & Ireland
[i] NICE (2015) Type 2 diabetes in adults: management
[ii] Diabetes UK (2014) State of The Nation: Challenges for 2015 and beyond
[iii] HSCIC (2012) National Diabetes Audit 2011-2012. Report 2:Complications and Mortality
[iv] Boehringer Ingelheim (2015) Health Policy Briefing
Tuesday 20th October 2015 saw the Communications Team launch BI’s health policy briefing document in the Strangers Dining Room at the House of Commons. The policy document has been developed by the team to outline specific asks of the recently elected Government on issues such as NICE, the Pharmaceutical Price Regulation Scheme (PPRS), Specialised Commissioning and in the therapy areas where we major.
Coinciding with the State Visit to Parliament by the President of China, there was a moment when it looked like people weren’t going to be able to gain access to the building, but we remained calm and welcomed over 50 guests to our reception. These were made up of a wide range of our stakeholders, including MPs from all sides of the House, Lords with an interest in Health, staff from the Department of Health and NHS England – including the Chair of NICE and the National Clinical Director for Diabetes – and a range of clinical stakeholders who had come to hear what we had to say, along with representatives from patient organisations with whom we have been working closely over the last few years. Continue reading Health Policy Briefing Document launches at Reception in Parliament→
On Monday this week you may have seen in the news that the number of people diagnosed with diabetes in the UK has soared by 60%1 in the past decade. It was also mentioned that the spending on diabetes drugs has increased during that time and we can all appreciate that the financial resources available for paying for drugs in the UK are not limitless. It is important that money is spent on pharmaceutical clinical trials to assess safety, efficacy and more importantly the complications of diabetes which can be associated with substantial costs.
Barbara Young, the chief executive of Diabetes UK, said the government needed1 to act to prevent new cases and improve treatment for those already affected. She said: “Diabetes already costs the NHS nearly £10bn a year, and 80% of this is spent on managing avoidable complications. So there is huge potential to save money and reduce pressure on NHS hospitals and services through providing better care to prevent people with diabetes from developing devastating and costly complications,” she added.
So the focus cannot be simply on the laboratory blood glucose values for a patient with diabetes but should be on providing treatments that reduce the risk of diabetes related complications.
In addition, pharmaceutical management should be on clinical guidelines that support an individualized approach to diabetes care.